Carl J. Gonzalez
Phone: 610-***-****
**********@*******.***
Strategic and results driven Vice President of Business Development with 15 + years of consultative business-to-business (B2B) selling experience with CRO’s and CDMO’s as both a sole contributor, or in sales team leadership positions. In depth knowledge of small molecule product development, process development, clinical trial sponsor enrollment, and API commercial manufacturing. Extensive pharmaceutical contacts/relationships in the East Coast Region of the US. Proven record of converting pharmaceutical client outsourcing opportunities into closed sales.
Sr. Director Business Development North America January 2023 – August 2026
Raffles Pharma Tech. (CDMO)
Identify and close new BD R&D pipeline development projects matching Raffles full service, end-to-end, CMC pre-clinical development capabilities from early-stage
API formulation, to kilo batch scale ups, clinical trial product support, and full-scale API commercial manufacturing.
Successful national introductory promotional effort to increase knowledge of Raffles DS CDMO capabilities resulting in new RFP requests from several start up, and medium sized pharma. companies with near term product development outsourcing requirements
On plan to achieve company sales goal of closing $ 6.0 million dollar sales goal by year’s end. Managing Raffles marketing & trade show programs including Website updates, development of printed materials, trade show attendance, to
Promote industry wide introduction of Raffles CDMO full “ end to end” service capabilities.
Extensive R&D business contacts/relationships in Small, Medium, & Large pharmaceutical organizations.
Director Business Development Mid-Atlantic Region Sept. 2017- December 2022
Recipharm AB ( CDMO)
Responsible for promoting Recipharm’s multinational “end-to end” pharmaceutical manufacturing services across various dosage forms, including sterile fill & finish, oral solid dosage, biologics, provide clinical trial material development as well as full scale manufacturing services.
Consistently attained $4 million annual dollar sales quotas by bringing in CMC early product development small molecule projects.
Brought in several new logos including “Big Pharma” customers, e.g. Merck, Novo Nordisk, GSK.
Negotiated and closed business product development commercial scale mfg. branded product tech transfer projects.
National Director Marketing – Business Development September 2015 – August 2017
Ascendia Pharmaceuticals (CRO)
Developed new marketing materials and Website for Ascendia to promote the company’s proprietary nano-technology product development expertise. National BD Director responsible for identifying pharmaceutical prospects interested employing nano technology as a novel means of solving “challenging” drug release problems. Provided hands on close customer project management support from the proposal stages to project completions.
Identified & finalized formulation development projects with several emerging pharmaceutical companies requiring nano technology formulation approaches to overcome “challenging” formulation obstacles.
On track to attain assigned sales quota attainment of six million dollar sales goal
Brought in new clinical trial manufacturing projects involving oral & parenteral trial support (protocols & trial materials Phases 1-2). Extensive R&D business contacts/relationships in Small, Medium, & Large pharmaceutical organizations.
Extensive R&D business contacts/relationships with research & outsourcing managers in emerging and “big pharmaceutical” organizations with active new product development programs.
Manager Business Development & Ket Accounts February 2014 – July 2015
Quantex Labs. (CRO)
Identify & develop new pharmaceutical clients requiring outsourced pre-clinical analytical, API formulation development or clinical trial protocol development or trial materials to support clinical trials. Identify outsourcing opportunities in pharmaceutical, Biotech, and Chemical companies. Manage current key accounts, promoted Quantex full testing services providing comprehensive analytical services and clinical support.
Attained a $2 million dollar annual sales quota in in 2014 for new customer laboratory testing services.
Significantly increased Quantex testing capabilities for comprehensive lab services NJ/PA/NY territory.
Very knowledgeable regarding pre-clinical lab testing procedures, clinical support, and equipment alternative testing equipment LC-MS, GC-MS, NMR, Mass Spec., etc.
Business Development/ Major Accounts Manager September 2012 – January 2014
Frontage Laboratories Inc. (CRO)
Promoted Frontage Labs. fully integrated CRO/CMO capabilities including CGMP API compound synthesis, analytical services, LC/MS/MS method development, stability testing, sample management, pharmacokinetic studies, preparation of early phase 1 & 2 clinical trial materials. Responsible for identifying & closing new business opportunities with biotechnology, start-up “small” Rx specialty companies, and large pharmaceutical. R&D organizations.
Develop relationships with key R&D personnel involved in Rx Discovery activities in both the laboratory, and project outsourcing support personnel, to encourage adoption of Frontage CRO services.
Met annual 5-million-dollar sales quota in the Eastern Territory, met sales objectives with emerging bio-tech, generic, and virtual pharma. companies in the Northeastern States.
Hands on management of new business accounts to ensure on time, on budget delivery of assigned project deliverables.
Extensive R&D business contacts/relationships with research & outsourcing managers in emerging and “big pharmaceutical” organizations with active new product development programs.
Education:
University of Miami- B.S. in Bio Chemistry/Biology
Thunderbird
Graduate School – MBA International Business